RxDoctor Payments Data

Jeremy Dumas, MD

Internal Medicine · New Orleans, LANPI 1104808757

Payments from drug & device makers

$768in general payments, 2019–2025

Across 28 payments — averaging $27.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$161
  • Lilly USA, LLC$154
  • Itamar Medical Inc$97
  • Hologic Sales And Service, LLC$78
  • Boehringer Ingelheim$63
  • Novo Nordisk$40
  • plus $175 from 6 others

What the payments were for

  • Food & beverage$768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$768 in reported general payments places this provider in the 60th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$376
Medicare patients
15
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide130$132,514
TrulicityDulaglutide92$123,238
OzempicSemaglutide73$79,119
JardianceEmpagliflozin47$67,580
Tresiba Flextouch U-200Insulin Degludec12$13,890
LinzessLinaclotide13$10,807
SymbicortBudesonide/Formoterol Fumarate19$4,263
Novolog FlexpenInsulin Aspart15$2,887
Lidocaine32$2,532
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,011
Losartan Potassium162$1,595
Azelastine Hcl45$1,415
Atorvastatin Calcium197$1,290
ValacyclovirValacyclovir Hcl37$1,274
Albuterol Sulfate HfaAlbuterol Sulfate57$1,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$154$255,753222 claims
Novo NordiskOzempic$40$79,11973 claims
Boehringer IngelheimJardiance$63$67,58047 claims
AstraZenecaSymbicort$39$4,26319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →